Search results
Showing 1151 to 1200 of 1326 results for nice quality standards or clinical guidelines
Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.
This indicator covers tooth extractions due to decay for children admitted as inpatients to hospital, aged 10 years and under. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults.
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Show all sections
Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults.
Self-expanding implant insertion into the intersphincteric space for faecal incontinence (HTG564)
Evidence-based recommendations on self-expanding implant insertion into the intersphincteric space for faecal incontinence. This involves inserting implants that expand and press together, forming a ring that creates an artificial sphincter.
View recommendations for HTG564Show all sections
BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume (MIB50)
NICE has developed a medtech innovation briefing (MIB) on the BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume
Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.
View recommendations for HTG171Show all sections
Sections for HTG171
Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults.
Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.
Show all sections
Endo-SPONGE for treating low rectal anastomotic leak (HTG605)
Evidence-based recommendations on Endo-SPONGE for treating low rectal anastomotic leak.
Help us improve NICE: take part in research to help us develop better products and services.
Help us improve NICE: take part in research to help us develop better products and services.
This indicator covers the percentage of diagnoses of sore throat in the preceding 12 months with a recorded FeverPain or Centor score. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes (HTG721)
Evidence-based recommendations on endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes. This involves using heat to destroy the lining of the duodenum to encourage a new lining to grow.
View recommendations for HTG721Show all sections
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)
Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.
NICE's partners
Outside interests of the NICE board
Evidence summaries: new medicines – Interim process statement (PMG1)
This interim process statement sets out to guide the development of 'Evidence summaries: new medicines' (ESNMs). It provides an overview of the key process principles and describes all stages of the development of ESNMs
This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process
NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .
Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes (HTG371)
Evidence-based recommendations on implantation of a duodenal-jejunal bypass liner for managing type 2 diabetes. This involves attaching a liner as a barrier between food and the upper part of the bowel, with the aim of lowering blood sugar levels.
Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTG676)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders.
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)
Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.
Healthy start vitamins: special report on cost effectiveness (ECD5)
This document describes a special report on the cost effectiveness of moving the Healthy Start vitamin programme from the current targeted offering to a universal offering
Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension (HTG741)
Evidence-based recommendations on alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension. This involves putting alcohol into the wall of a renal artery to destroy renal nerves.
View recommendations for HTG741Show all sections
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)
NICE has developed a medtech innovation briefing (MIB) on Xpert GBS test for the intrapartum detection of group B streptococcus
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)
Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.
Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.
Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids (MIB255)
NICE has developed a medtech innovation briefing (MIB) on the Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids .
Breast reconstruction using lipomodelling after breast cancer treatment (HTG280)
Evidence-based recommendations on breast reconstruction using lipomodelling after breast cancer treatment. This involves taking fat from the abdomen or thighs and injecting it into the breast in the area of the deformity caused by surgery.
View recommendations for HTG280Show all sections
Sections for HTG280
The standing committees were responsible for the development of our public health guidance.
Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.
Recommendation ID NG144/5 Question What is the clinical and cost effectiveness of cannabis-based medicinal products other than THC: CBD
Testing strategies for Lynch syndrome in people with endometrial cancer (HTG557)
Evidence-based recommendations on testing strategies for Lynch syndrome for people with endometrial cancer.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.
Evidence-based recommendations on therapeutic hypothermia for acute ischaemic stroke in adults. This involves using a cooling device to reduce the body’s temperature after a stroke.
View recommendations for HTG511Show all sections
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.
How we collect and use your personal information, and your rights under data protection legislation.
Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults.
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)
Evidence-based recommendations on cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda) for treating late-onset Pompe disease in adults.
Sorafenib for treating advanced hepatocellular carcinoma (TA474)
Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.
Evidence-based recommendations on PneuX to prevent ventilator-associated pneumonia.
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency in adults.
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.